CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.

Researchers at Oregon Health & Science University have discovered that pancreatic cancer cells reshape their environment by ...

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...

A new method of making cancer cells more visible to the immune system could improve how well immunotherapy works against a ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

RP1, in combination with Nivolumab, shrank tumors in about one-third of PD-1-failed melanoma patients. Shares of Replimune Group, Inc. (REPL) and Iovance Biotherapeutics, Inc. (IOVA) are back in focus ...

Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse. In this segment, Dr. Morrison provides clinical context ...

Healthcare professionals may use immunotherapy as part of the treatment for someone with Hodgkin’s lymphoma. They may also use it as part of palliative therapy to improve a person’s quality of life ...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has reached a significant ...